GlassScriptPhysician profile
Ramdas Nanda Kumar
NPI 1669631248
$13,219.71
in general payments reported to CMS, 2019-2025
33 companies · $5,462 in 2025
The $5,462 reported for 2025 was more than what 93% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,021 · 2020: $1,092 · 2021: $1,028 · 2022: $827 · 2023: $1,240 · 2024: $2,549 · 2025: $5,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,947 · Consulting Fee: $3,285 · Education: $18.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,947.07 |
| Consulting Fee | $3,285.00 |
| Education | $18.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,051.43 | 2019-2025 | Krystexxa, Tavneos, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,825.39 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $712.10 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $553.54 | 2021-2025 | |
| Horizon Therapeutics Plc | $500.81 | 2019-2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $471.64 | 2019-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $407.14 | 2019-2025 | |
| Vifor Pharma, INC. | $373.73 | 2019-2022 | |
| Glaxosmithkline, LLC. | $308.17 | 2022-2025 | Benlysta, Jesduvroq |
| Mallinckrodt Hospital Products INC. | $277.32 | 2020-2025 | Acthar |
| Novo Nordisk INC | $277.08 | 2019-2025 | Ozempic |
| Aurinia Pharma U.S., INC. | $233.09 | 2021-2025 | Lupkynis |
| Lilly USA, LLC | $221.14 | 2019-2025 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.03 | 2020-2025 | Jardiance |
| Akebia Therapeutics INC | $197.62 | 2021-2025 | Vafseo, Auryxia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $169.30 | 2019 | |
| Calliditas Therapeutics US INC. | $158.41 | 2023-2025 | Tarpeyo |
| Amarin Pharma, INC. | $149.04 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $148.66 | 2020-2021 | |
| Qiagen, LLC | $145.18 | 2020 | |
| Daiichi Sankyo INC. | $128.38 | 2019-2021 | |
| Abbvie INC. | $125.00 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $121.83 | 2024 | Inpefa |
| Travere Therapeutics, INC. | $96.06 | 2023-2025 | |
| Genzyme Corporation | $92.13 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $77.56 | 2022-2025 | Velphoro |
| Currax Pharmaceuticals LLC | $46.41 | 2021-2022 | |
| Scpharmaceuticals INC. | $44.08 | 2024-2025 | |
| Apellis Pharmaceuticals, INC. | $29.63 | 2025 | Empaveli |
| Ardelyx, INC. | $16.72 | 2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $15.75 | 2019 | |
| Amicus Therapeutics, INC. | $15.07 | 2019 | |
| Ani Pharmaceuticals, INC. | $13.27 | 2024 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramdas Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.